One should not buy Ranbaxy Laboratories, says Sudarshan Sukhani of s2analytics.com. "There is no support in the stock."
first published: May 24, 2013 07:01 pm
A collection of the most-viewed Moneycontrol videos.
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
Pine Labs’ Rs 3,900 Cr IPO| CEO Amrish Rau On Why The Issue Size Was Cut & The Post-IPO Gameplan
